COVID-19 and Acute Kidney Injury Outcomes in Hospitalized Patients Following SARS-CoV-2 Vaccination: A Case-Control Study
Background: Acute kidney injury (AKI) is a frequent complication associated with severe COVID-19 and has been linked to increased mortality. While vaccination against SARS-CoV-2 has shown effectiveness in reducing severe COVID-19 outcomes, its impact on the development of AKI among hospitalized pati...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-11-01
|
| Series: | Canadian Journal of Kidney Health and Disease |
| Online Access: | https://doi.org/10.1177/20543581241297369 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850194625837400064 |
|---|---|
| author | Froylan D. Martínez-Sánchez Luis A. Bastida-Castro José L. Torres-Cuevas Julio A. Vasquez-Vasquez Alejandra Diaz-Jarquin Rafael Moreno-Novales Joana Balderas-Juarez Mauricio A. Salinas-Ramírez Jose L. Hernández-Castillo Erika K. Tenorio-Aguirre |
| author_facet | Froylan D. Martínez-Sánchez Luis A. Bastida-Castro José L. Torres-Cuevas Julio A. Vasquez-Vasquez Alejandra Diaz-Jarquin Rafael Moreno-Novales Joana Balderas-Juarez Mauricio A. Salinas-Ramírez Jose L. Hernández-Castillo Erika K. Tenorio-Aguirre |
| author_sort | Froylan D. Martínez-Sánchez |
| collection | DOAJ |
| description | Background: Acute kidney injury (AKI) is a frequent complication associated with severe COVID-19 and has been linked to increased mortality. While vaccination against SARS-CoV-2 has shown effectiveness in reducing severe COVID-19 outcomes, its impact on the development of AKI among hospitalized patients remains unclear. Objective: To evaluate the effect of SARS-CoV-2 vaccination on the incidence and severity of AKI and 28-day mortality among hospitalized patients with severe COVID-19. Design: Retrospective case-control study. Setting: Conducted at the Internal Medicine Department of Hospital General Dr. Manuel Gea González, Mexico, from April 2020 to December 2021. Patients: 413 patients over 18 with confirmed severe COVID-19 were included. Patients were categorized based on their vaccination status before COVID-19 infection. Measurements: Key outcomes included the incidence of AKI, progression to AKI stage 3, and 28-day mortality. AKI was defined according to the KDIGO criteria. Methods: Data were analyzed using univariate and logistic regression models to assess the association between vaccination status and the studied outcomes. Covariates included age, sex, BMI, type 2 diabetes, hypertension, and inflammatory markers. Results: Among the 413 patients, 70% developed AKI, with a median hospital stay of 10 days (range 6-17). Vaccinated patients had a significantly lower incidence of AKI compared with nonvaccinated patients (48.7% vs 74.9%; P < .001). After adjusting for confounding factors, vaccination was associated with lower odds of AKI (OR: 0.252, 95% CI: 0.140-0.452), AKI stage 3 (OR: 0.448, 95% CI: 0.205-0.981), and 28-day mortality (OR: 0.187, 95% CI: 0.064-0.544). Limitations: As a single-center retrospective study, generalizability is limited. In addition, vaccination data were obtained from medical records, and the completeness of vaccination could not be independently verified. Conclusions: SARS-CoV-2 vaccination was independently associated with a reduced risk of AKI, AKI stage 3, and 28-day mortality in hospitalized patients with severe COVID-19. These findings highlight the potential protective effects of vaccination against severe kidney complications in this population. |
| format | Article |
| id | doaj-art-a11df1fe8a9849919b9130a27277cb9b |
| institution | OA Journals |
| issn | 2054-3581 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Canadian Journal of Kidney Health and Disease |
| spelling | doaj-art-a11df1fe8a9849919b9130a27277cb9b2025-08-20T02:13:56ZengSAGE PublishingCanadian Journal of Kidney Health and Disease2054-35812024-11-011110.1177/20543581241297369COVID-19 and Acute Kidney Injury Outcomes in Hospitalized Patients Following SARS-CoV-2 Vaccination: A Case-Control StudyFroylan D. Martínez-Sánchez0Luis A. Bastida-Castro1José L. Torres-Cuevas2Julio A. Vasquez-Vasquez3Alejandra Diaz-Jarquin4Rafael Moreno-Novales5Joana Balderas-Juarez6Mauricio A. Salinas-Ramírez7Jose L. Hernández-Castillo8Erika K. Tenorio-Aguirre9Facultad de Medicina, Universidad Nacional Autonoma de Mexico, MéxicoDepartment of Internal Medicine, Hospital General Dr. Manuel Gea González, Ciudad de México, MéxicoDepartment of Internal Medicine, Hospital General Dr. Manuel Gea González, Ciudad de México, MéxicoFacultad de Medicina, Universidad Nacional Autonoma de Mexico, MéxicoDepartment of Internal Medicine, Hospital General Dr. Manuel Gea González, Ciudad de México, MéxicoDepartment of Internal Medicine, Hospital General Dr. Manuel Gea González, Ciudad de México, MéxicoDepartment of Nephrology, Hospital General Dr. Manuel Gea Gonzalez, Ciudad de México, MéxicoDepartment of Nephrology, Hospital General Dr. Manuel Gea Gonzalez, Ciudad de México, MéxicoDepartment of Nephrology, Hospital General Dr. Manuel Gea Gonzalez, Ciudad de México, MéxicoDepartment of Internal Medicine, Hospital General Dr. Manuel Gea González, Ciudad de México, MéxicoBackground: Acute kidney injury (AKI) is a frequent complication associated with severe COVID-19 and has been linked to increased mortality. While vaccination against SARS-CoV-2 has shown effectiveness in reducing severe COVID-19 outcomes, its impact on the development of AKI among hospitalized patients remains unclear. Objective: To evaluate the effect of SARS-CoV-2 vaccination on the incidence and severity of AKI and 28-day mortality among hospitalized patients with severe COVID-19. Design: Retrospective case-control study. Setting: Conducted at the Internal Medicine Department of Hospital General Dr. Manuel Gea González, Mexico, from April 2020 to December 2021. Patients: 413 patients over 18 with confirmed severe COVID-19 were included. Patients were categorized based on their vaccination status before COVID-19 infection. Measurements: Key outcomes included the incidence of AKI, progression to AKI stage 3, and 28-day mortality. AKI was defined according to the KDIGO criteria. Methods: Data were analyzed using univariate and logistic regression models to assess the association between vaccination status and the studied outcomes. Covariates included age, sex, BMI, type 2 diabetes, hypertension, and inflammatory markers. Results: Among the 413 patients, 70% developed AKI, with a median hospital stay of 10 days (range 6-17). Vaccinated patients had a significantly lower incidence of AKI compared with nonvaccinated patients (48.7% vs 74.9%; P < .001). After adjusting for confounding factors, vaccination was associated with lower odds of AKI (OR: 0.252, 95% CI: 0.140-0.452), AKI stage 3 (OR: 0.448, 95% CI: 0.205-0.981), and 28-day mortality (OR: 0.187, 95% CI: 0.064-0.544). Limitations: As a single-center retrospective study, generalizability is limited. In addition, vaccination data were obtained from medical records, and the completeness of vaccination could not be independently verified. Conclusions: SARS-CoV-2 vaccination was independently associated with a reduced risk of AKI, AKI stage 3, and 28-day mortality in hospitalized patients with severe COVID-19. These findings highlight the potential protective effects of vaccination against severe kidney complications in this population.https://doi.org/10.1177/20543581241297369 |
| spellingShingle | Froylan D. Martínez-Sánchez Luis A. Bastida-Castro José L. Torres-Cuevas Julio A. Vasquez-Vasquez Alejandra Diaz-Jarquin Rafael Moreno-Novales Joana Balderas-Juarez Mauricio A. Salinas-Ramírez Jose L. Hernández-Castillo Erika K. Tenorio-Aguirre COVID-19 and Acute Kidney Injury Outcomes in Hospitalized Patients Following SARS-CoV-2 Vaccination: A Case-Control Study Canadian Journal of Kidney Health and Disease |
| title | COVID-19 and Acute Kidney Injury Outcomes in Hospitalized Patients Following SARS-CoV-2 Vaccination: A Case-Control Study |
| title_full | COVID-19 and Acute Kidney Injury Outcomes in Hospitalized Patients Following SARS-CoV-2 Vaccination: A Case-Control Study |
| title_fullStr | COVID-19 and Acute Kidney Injury Outcomes in Hospitalized Patients Following SARS-CoV-2 Vaccination: A Case-Control Study |
| title_full_unstemmed | COVID-19 and Acute Kidney Injury Outcomes in Hospitalized Patients Following SARS-CoV-2 Vaccination: A Case-Control Study |
| title_short | COVID-19 and Acute Kidney Injury Outcomes in Hospitalized Patients Following SARS-CoV-2 Vaccination: A Case-Control Study |
| title_sort | covid 19 and acute kidney injury outcomes in hospitalized patients following sars cov 2 vaccination a case control study |
| url | https://doi.org/10.1177/20543581241297369 |
| work_keys_str_mv | AT froylandmartinezsanchez covid19andacutekidneyinjuryoutcomesinhospitalizedpatientsfollowingsarscov2vaccinationacasecontrolstudy AT luisabastidacastro covid19andacutekidneyinjuryoutcomesinhospitalizedpatientsfollowingsarscov2vaccinationacasecontrolstudy AT joseltorrescuevas covid19andacutekidneyinjuryoutcomesinhospitalizedpatientsfollowingsarscov2vaccinationacasecontrolstudy AT julioavasquezvasquez covid19andacutekidneyinjuryoutcomesinhospitalizedpatientsfollowingsarscov2vaccinationacasecontrolstudy AT alejandradiazjarquin covid19andacutekidneyinjuryoutcomesinhospitalizedpatientsfollowingsarscov2vaccinationacasecontrolstudy AT rafaelmorenonovales covid19andacutekidneyinjuryoutcomesinhospitalizedpatientsfollowingsarscov2vaccinationacasecontrolstudy AT joanabalderasjuarez covid19andacutekidneyinjuryoutcomesinhospitalizedpatientsfollowingsarscov2vaccinationacasecontrolstudy AT mauricioasalinasramirez covid19andacutekidneyinjuryoutcomesinhospitalizedpatientsfollowingsarscov2vaccinationacasecontrolstudy AT joselhernandezcastillo covid19andacutekidneyinjuryoutcomesinhospitalizedpatientsfollowingsarscov2vaccinationacasecontrolstudy AT erikaktenorioaguirre covid19andacutekidneyinjuryoutcomesinhospitalizedpatientsfollowingsarscov2vaccinationacasecontrolstudy |